October 2024—Pillar Biosciences has entered into a strategic partnership with AstraZeneca to expand laboratory access to molecular testing using rapid next-generation sequencing–based liquid biopsy tumor profiling panels for detecting genetic cancer variants. The partnership aims to make liquid biopsy tumor profiling more accessible to local laboratories, clinicians, and patients through rapid and affordable kitted NGS testing solutions.
“Access to cost-effective, easy to use, distributed NGS kits for liquid biopsy testing are critical to support local laboratories in providing clinically actionable results to oncologists and supporting critical treatment decisions for cancer patients globally,” Dan Harma, chief commercial officer of Pillar Biosciences, said in a press release. “Pillar Biosciences LBx panels, including OncoReveal Core LBx, OncoReveal Essential LBx, and OncoReveal Fusion LBx, will help provide in-house results locally within a few days versus several weeks to receive results from sending out their patient samples for most clinical laboratories.”
The partnership will initially focus on European and U.K. markets.
Pillar Biosciences, 508-655-3027